La cadena de opciones muestra datos clave de las opciones de acciones de Rocket Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Rocket Pharmaceuticals..

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa, Cadena de Opciones

ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Descubre qué acciones sobrevendidas del sector salud tienen un RSI por debajo de 30 y podrían estar infravaloradas.

3 acciones estadounidenses de atención médica que podrían despegar este mes

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals Inc

ROCK TECH LINTHIUM INC by Rock Tech Lithium Inc.

Rock Tech Lithium Inc

Economist Peter Schiff has publicly criticized &#8220;The Big Short&#8221; fame investor Steve Eisman for <a href="https://www.benzinga.com/markets/equities/25/04/44830819/big-short-fame-steve-eisman-says-nvidias-best-days-are-not-behind-it-but-trump-is-the-wild-card-in-current-market">dismissing both gold investments and U.S. national debt concerns</a> during a recent media interaction. The exchange highlights growing tensions among financial experts over monetary policy and fiscal sustainability.
What Happened: Schiff wrote on X that Eisman&#8217;s stance reveals &#8220;incredible irony.&#8221; During the CNBC <a href="https://www.youtube.com/watch?v=qXR69STpehE">interview</a>, Eisman stated he&#8217;s &#8220;not a gold guy&#8221; and doesn&#8217;t monitor gold markets closely. He also expressed confidence in U.S. Treasuries, arguing he&#8217;s not worried about the $36.22 trillion national debt &#8220;so long as the world doesn&#8217;t have an alternative to Treasuries.&#8221;
The criticism comes as gold trades near $2,360 per ounce after pulling back from recent highs, while Treasury yields remain elevated with the 10-year note at 4.45% and 20-year bonds yielding 4.95%. Recent Moody&#8217;s credit rating concerns have pushed 30-year Treasury yields to near 5%, <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45500872/30-year-treasury-yields-hit-5-what-that-means-for-stocks">levels not seen since October 2023</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big Short investor Steve Eisman just told <a href="https://twitter.com/CNBC?ref_src=twsrc%5Etfw">@CNBC</a> he&#39;s not a gold guy and doesn&#39;t watch or care about gold. He then said he&#39;s not worried about the U.S. national debt so long as the world doesn&#39;t have an alternative to Treasuries. The irony of those two statements is incredible.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1929651223235596479?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/politics/25/06/45740331/trumps-man-to-man-diplomacy-wont-work-with-xi-jinping-warns-former-white-house-chief-of-staff-as-tariff-deadlock-continues">Trump&#8217;s &#8216;Man-To-Man&#8217; Diplomacy Won&#8217;t Work With Xi Jinping, Warns Former White House Chief Of Staff As Tariff Deadlock Continues</a>
Why It Matters: Eisman, former senior portfolio manager at Neuberger Berman Group Inc. and current host of &#8220;The Real Eisman Playbook&#8221; podcast, gained fame for profiting from the 2008 subprime mortgage crisis. 
During his interview, he expressed caution about current markets, citing tariff uncertainties as his primary concern while maintaining positions in mega-cap technology stocks.
When challenged on social media about investment performance comparisons, one user noted that Eisman&#8217;s subprime short generated over $1 billion compared to potential gold returns of $40-80 million during the same period. However, Schiff countered that current conditions present different opportunities, calling U.S. dollars and Treasuries &#8220;the next big short.&#8221;
Schiff defended his macro analysis expertise, noting he also participated in subprime shorting but maintains &#8220;a much better understanding of global macro&#8221; dynamics. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That was then. This is now. He is missing the next big short. The U.S. dollar and treasuries.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1929685857742868691?ref_src=twsrc%5Etfw">June 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/futures/25/06/45740778/us-stocks-likely-to-open-lower-expert-highlights-technical-analysis-showing-sp-500s-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&amp;P 500&#8217;s &#8216;Recovery Is Real&#8217; And Not A &#8216;Bull Trap&#8217; Or &#8216;Bear Market Rally&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Bonds

Peter Schiff Calls Out 'The Big Short' Investor Steve Eisman For Dismissing Gold And US Debt Concerns: 'The Irony Is Incredible'

HC Wainwright &amp; Co. analyst Scott Buck reiterates Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

YTRA

HC Wainwright & Co. Reiterates Buy on Yatra Online, Maintains $3 Price Target

UUUU

Energy Fuels Reports Record Uranium Production and Expands Resource Base With New Bullfrog Technical Report And Accelerated U.S. Permitting

National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.20 by 30 percent. This is a 6.67 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $303.10 million which missed the analyst consensus estimate of $341.73 million by 11.30 percent. This is a 2.11 percent increase over sales of $296.85 million the same period last year.

Earnings

Earnings Misses

NESR

National Energy Services Q1 Adj. EPS $0.14 Misses $0.20 Estimate, Sales $303.10M Miss $341.73M Estimate

WTER

The Alkaline Water Company Expands National Footprint With Strategic Distribution Agreement Covering 16,000 Locations Across 32 States

Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally defined as a failure on two or more antidepressants.
The most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for the treatment of Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 is designed to enable rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. ALTO-207 is being developed to address the significant unmet need for patients with TRD.
"The expansion of our pipeline aligns with Alto's mission to drive innovation in psychiatry through novel therapeutic solutions," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "With proprietary insights on dopamine biomarkers in depression that enable targeted neuropsychiatric drug development, we are uniquely positioned to advance ALTO-207, a differentiated, late-stage product candidate with robust clinical effects to date, which are supported with historical pramipexole data. The fixed-dose combination of pramipexole and ondansetron offers a novel treatment strategy designed to optimize for a rapid treatment effect with faster titration, and balance safety and tolerability at high doses. We believe the convenience of a single prescribable agent will also improve compliance and support clinician and patient adoption. Leveraging our targeted biomarker approach to stratify for TRD patients most likely to respond to treatment, we look forward to building on the positive Phase 2a results and initiating a Phase 2b trial, with a potentially pivotal design, by mid-2026."
Dr. Etkin continued, "The strategic transaction with Chase Therapeutics allows us to add a major late-stage clinical readout to our pipeline without changing our current cash runway guidance into 2028. Broadly, we believe this opportunity underscores the robust value of our precision platform and bolsters our prospects for long-term growth through driving innovation in psychiatry."
Thomas Chase, M.D., President and Chief Executive Officer of Chase Therapeutics Corporation, added, "Supported by the robust clinical effects in our completed Phase 2a study, we believe CTC-501, has the potential to address the critical need for more effective, mechanistically distinct interventions for patients with TRD. Given Alto's expertise in dopamine-related products in depression, we believe they are an ideal partner to maximize the therapeutic potential of our portfolio in depression and Parkinson's disease. We look forward to seeing Alto continue this exciting momentum as they work toward realizing our shared vision for patients."
Michael Browning, DPhil, MB.BS, MRCP, MRCPsych, Professor of Computational Psychiatry, University of Oxford, commented, "I am highly encouraged by the recently completed PAX-D study of pramipexole, which suggests a greater and more durable effect than other available TRD treatments. However, pramipexole is not well tolerated and when it is, it requires slow titration due to dose-limiting AEs. The clinical utility of pramipexole would be greatly enhanced by improving the dose-limiting tolerability profile. Emerging data suggests that ALTO-207 could address these challenges, and be well positioned to treat this large and underserved patient population."
Alto acquired CTC-501 (now ALTO-207), in development for depression, and CTC-413 (now ALTO-208), in development for Parkinson's disease. Both product candidates are novel patent-protected dopamine agonists.
About the Completed Phase 2a Trial for CTC-501
Chase Therapeutics completed a randomized, placebo-controlled Phase 2a clinical trial evaluating CTC-501 in 32 patients with depression. The study consisted of two periods, a dose titration period in which patients were dosed with increasing dose levels of CTC-501 or placebo at increments of 1 mg/day (or matching placebo) until the maximum allowed dose (or first intolerable dose) was reached. Patients were then maintained for an eight-week treatment period at either the maximum allowed dose or their maximum tolerated dose (1 mg/day lower than their first intolerable dose in the titration period). The primary endpoint in the study was defined as overall tolerability and achievement of higher dose levels of pramipexole when combined with ondansetron. Clinical efficacy was evaluated as a secondary exploratory endpoint in the study.
The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day with 67% of patients achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study.
The clinical efficacy measures were evaluated as secondary endpoints and across measures CTC-501 demonstrated large, clinically meaningful, effects. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scalef, or MADRS (LSM Δ vs. placebo at Week 8 = -8.2, p=0.025, Cohen's d=1.1). CTC-501 also demonstrated a significantly greater improvement compared to placebo on the Clinician Global Impression Scale of Severity, or CGI-S (LSM Δ vs. placebo at Week 8 = -0.76, p=0.04, Cohen's d=1.0).
About the Completed Phase 2a Trial for CTC-413
ALTO-208 is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD).
Chase Therapeutics completed a blinded Phase 2a clinical trial evaluating CTC-413 (pramipexole co-administered with aprepitant) in 13 patients with PD. The study consisted of two periods. Patients in the treatment group were initially titrated to the maximum allowed dose of standard pramipexole extended release (4.5 mg/day). Patients were then switched to CTC-413 until the maximum allowed dose of 9mg/day (or first intolerable dose) was reached. Following three months of maintenance, patients returned to their pre-study regimen for final assessment.
The mean tolerated dose of CTC-413 significantly exceeded pramipexole (p&lt;0.001). Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues.
About the Transaction
Under the terms of the asset purchase agreement, Alto paid Chase Therapeutics an upfront payment of $1.75 million, and Chase Therapeutics will be eligible for up to an aggregate of $71.5 million in future milestone payments related to prespecified development and commercial milestones. $41 million of the potential future milestone payments are tied to commercial success of the product candidates.
Alto's financial guidance remains unchanged. The Company expects its current cash balance to support planned operations into 2028, now through five clinical trial readouts across its pipeline programs.

ANRO

Alto Buys Depression and Parkinson's Drug Portfolio for $1.75M Upfront, With $71.5M in Future Milestones

Guidance

Donaldson Revised Guidance For FY25 Sales To Be Up 1% To 3% (From Flat To Up 4% Earlier)

Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) raises FY2025 Adj EPS guidance from $3.60-$3.68 to $3.64-$3.70 vs $3.60 analyst estimate..

Donaldson Raises FY2025 Adj EPS Guidance from $3.60-$3.68 to $3.64-$3.70 vs $3.60 Est

Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) ("Cango" or the "Company") today announced its production update for crypto mining business in May 2025.
&nbsp;
Bitcoin Mining Update for May 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metrics</td>
<td colspan="1" rowspan="1">May 2025 1</td>
<td colspan="1" rowspan="1">Apr 2025 1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Number of Bitcoins produced</td>
<td colspan="1" rowspan="1">484.5</td>
<td colspan="1" rowspan="1">470.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average number of Bitcoins produced per day</td>
<td colspan="1" rowspan="1">15.63</td>
<td colspan="1" rowspan="1">15.67</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total number of Bitcoins held 2</td>
<td colspan="1" rowspan="1">3,429.3</td>
<td colspan="1" rowspan="1">2,944.8</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total number of Bitcoins sold 2</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deployed hashrate 2</td>
<td colspan="1" rowspan="1">32 EH/s</td>
<td colspan="1" rowspan="1">32 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average operating hashrate 3</td>
<td colspan="1" rowspan="1">29.86 EH/s</td>
<td colspan="1" rowspan="1">29.94 EH/s</td>
</tr>
</tbody>
</table>
</figure>

CANG

Cango Mines 484.5 Bitcoins in May, Boosts Holdings to Over 3,400 Without Selling Any

Future Fund LLC's managing director, Gary Black, thinks Elon Musk's Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) needs a pickup truck with a more conventional design as Cybertruck deliveries plunge.
What Happened: "With Cybertruck FY'25 deliveries currently tracking at just ~20,000, it's time for $TSLA to consider a cheaper (~$40-$50K), more conventional-looking Tesla pickup to capitalize on the global pickup truck opportunity," the investor said in a post on X on Tuesday.
He also outlined how, unlike a scaled-down Model Y, the new truck with some design cues from the new Model Y, "would likely have minimal cannibalization on existing TSLA models," Black said.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45739688/ford-recalls-over-29500-f-150-lightning-pickup-trucks-over-suspension-defect">Ford Recalls Over 29,500 F-150 Lightning Pickup Trucks Over Suspension Defect</a>
The investor finally shared that if Musk's EV giant can capture at least 2% of the global pickup truck sector, it "could translate to incremental earnings of $800M, worth potentially $80B ($25/share) at a 100x P/E," Black noted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With Cybertruck FY'25 deliveries currently tracking at just ~20,000, it's time for <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> to consider a cheaper (~$40-$50K), more conventional-looking Tesla pickup to capitalize on the global pickup truck opportunity (6-7% of industry volume ~6M annual TAM). Unlike a scaled-down…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1929793773766164808?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Black's comments come as the Cybertruck is proving to be a difficult product to sell for Musk and Tesla. The company reportedly has over <a href="https://www.benzinga.com/markets/25/05/45216453/tesla-has-over-10000-units-of-unsold-cybertrucks-in-its-us-inventory-amid-poor-sales-report">10,000 units of unsold Cybertrucks </a>in its U.S. inventory, demonstrating the product's lack of appeal among traditional pickup buyers.
The EV giant even revamped the <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">Cybertruck's marketing strategy</a> to position the vehicle as a utilitarian workhorse with visuals of the Cybertruck hauling a trailer, tackling a dirt road, as well as hauling construction material.
Meanwhile, the company has also started <a href="https://www.benzinga.com/25/05/45487522/tesla-is-accepting-trade-ins-for-2024-cybertruck-amid-plummeting-sales-figures-report">accepting trade-ins </a>for the Cybertruck just over a year after the product launched. Tesla reportedly offered $65,400 for an All-wheel-drive 2024 Cybertruck with 6,211 miles to a Cybertruck owner as a trade-in.
Elsewhere, Black recently shared that his firm offloaded its remaining stake in Tesla, a move that was in line with <a href="https://www.benzinga.com/markets/equities/25/06/45737979/cathie-wood-sells-tesla-stock-as-chinese-rivals-gain-ground-ark-dumps-palantir-amid-privacy-concerns">other expert analysts </a>like Cathie Wood and even insiders like Musk's brother, Kimbal Musk.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="184" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1024x184.jpg" alt="" class="wp-image-936305" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1024x184.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-300x54.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-768x138.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1-1536x277.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03051655/TSLA-JUN-3-2025-1-1.jpg 1649w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
TSLA scores well on Momentum, Growth, and Quality metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45740083/elon-musks-tesla-files-new-autonomous-taxi-trademark-application-ahead-of-robotaxi-launch-in-june">Elon Musk&#8217;s Tesla Files New Autonomous Taxi Trademark Application Ahead Of Robotaxi Launch In June</a></li>
</ul>
Photo courtesy: Jonathan Weiss / Shutterstock.com

Tech

TSLA

Tesla Needs To Consider A 'More Conventional-Looking' Pickup Truck Says Gary Black Amid Cybertruck Sales Slump

SMNEY

Eaton And Siemens Energy Partner To Deliver Modular, Grid-Independent Power Solutions For Rapid Data Center Deployment

Donaldson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) reported quarterly earnings of $0.99 per share which met the analyst consensus estimate. This is a 7.61 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $940.10 million which missed the analyst consensus estimate of $943.02 million by 0.31 percent. This is a 1.31 percent increase over sales of $927.90 million the same period last year.

Donaldson Q3 Adj. EPS $0.99, Inline, Sales $940.10M Miss $943.02M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy and maintains $80 price target.

PTGX

HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $80 Price Target

Tom Cruise-starrer <a href="https://www.benzinga.com/news/23/10/35388413/hollywood-strike-pushes-mission-impossible-to-2025-paramount-adjusts-release-calendar">high-octane blockbuster</a> "Mission: Impossible – The Final Reckoning" reignited China's box office over the weekend, topping charts and signaling renewed interest in Hollywood imports.
What Happened: Paramount Global's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) "Mission: Impossible – The Final Reckoning" debuted at No. 1 in China from May 30 to June 1, earning 184.5 million yuan ($25.6 million), <a href="https://variety.com/2025/film/news/tom-cruise-mission-impossible-china-box-office-1236415430/">reported</a> Variety, citing Artisan Gateway.
The film's strong performance was bolstered by premium formats, with IMAX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) screenings contributing $4.9 million, making it IMAX's biggest opening for a Hollywood film in China this year.
In second place was the Chinese animated fantasy "Endless Journey of Love," which grossed $7.6 million. The film, set in 1930s China, follows a young woman who gains the power to manipulate time.
See Also:&nbsp;<a href="https://benzinga.com/markets/equities/25/04/44862552/ford-recalls-nearly-150000-vehicles-over-brake-and-powertrain-issues-nhtsa" target="_blank" rel="noreferrer noopener">Ford Recalls Nearly 150,000 Vehicles Over Brake And Powertrain Issues: NHTSA</a>
Japan's "Doraemon: Nobita's Art World Tales" debuted third with $7.5 million.
Walt Disney Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) live-action "Lilo &amp; Stitch" slipped to fourth in its second weekend, earning $6.6 million and pushing its total to $17.8 million, the report noted.
Hong Kong action thriller "Behind the Shadows" rounded out the top five with a $4.3 million debut.
Why It's Important: The strong debut of Mission: Impossible marks a notable rebound for Hollywood in China's competitive film market.
MAX CEO Rich Gelfond called the China results encouraging, especially ahead of more Hollywood tentpoles scheduled for release this summer.
Overall, the weekend's box office totaled $58.2 million, reflecting growing momentum.
China's year-to-date box office now stands at $3.82 billion, up 26.6% from the same period in 2024, indicating a healthy recovery in theatrical attendance and international film reception.
Benzinga's Edge Stock Rankings show that Paramount is experiencing a positive price trend across the short, medium, and long term. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">You can explore more detailed metrics here</a>.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03052116/Screenshot-2025-06-03-at-2.48.40%E2%80%AFPM.png" alt="" class="wp-image-936310" /></a></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/25/04/44855242/charlie-munger-once-highlighted-how-warren-buffetts-lifelong-learning-made-berkshire-hathaways-success-possible-and-the-crucial-lesson-you-can-take-from-it" target="_blank" rel="noreferrer noopener">Charlie Munger Once Said Warren Buffett Is A ‘Learning Machine' And That's What Lies Beneath Berkshire Hathaway's Success From One Decade To Another</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Featureflash Photo Agency / Shutterstock.com

Entertainment

Media

IMAX

PARA

PARAA

Tom Cruise's 'Mission: Impossible – The Final Reckoning' Smashes China Box Office With $25.6 Million Opening, Sets IMAX Record For Hollywood Films In 2025

Needham analyst Mayank Tandon reiterates ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) with a Buy and maintains $55 price target.

EXLS

Needham Reiterates Buy on ExlService Hldgs, Maintains $55 Price Target

Needham analyst Mike Matson reiterates TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Hold to Hold.

TMDX

Needham Reiterates Hold on TransMedics Groupto Hold

U.S. stock futures fell on Tuesday, pulling back after a higher close on Monday. Futures of major benchmark indices declined in premarket.
Trade tensions escalated as <a href="https://www.benzinga.com/news/politics/25/06/45715447/xi-jinpings-china-dismisses-trumps-groundless-accusations-on-geneva-trade-deal-breach-vows-strong-retaliation">China&#8217;s Commerce Ministry dismissed</a> President Donald Trump&#8216;s allegations that Beijing had violated the Geneva trade agreement. The ministry asserted that China had fully implemented and consistently honored the deal struck last month in Geneva.
The Chinese government declared that the U.S. had &#8220;groundlessly&#8221; accused China of breaching the trade agreement. It pledged to take strong action to protect its interests.
Meanwhile, the 10-year Treasury bond yielded 4.41% and the two-year bond was at 3.92%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 95.3% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.43%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.42%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.49%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Tuesday. The SPY was down 0.45% at $590.04, while the QQQ declined 0.36% to $521.35, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
U.S. stocks wrapped up Monday higher. Most sectors within the S&amp;P 500 ended positively, spearheaded by strong performances in energy, communication services, and information technology stocks. However, industrial stocks went against the grain, finishing the session lower.
Wall Street closed out last month strong, with the S&amp;P 500 up more than 6.2% in May and the Nasdaq surging 9.6%. Both indices had their best months since November 2023, while the Dow gained 3.9% for the month.
Trade tensions flared as President Trump announced weekend plans to <a href="https://www.benzinga.com/news/topics/25/05/45708977/trump-doubles-steel-tariffs-to-50-saying-it-will-secure-american-jobs-backs-us-steels-takeover-by-japans-nippon">double tariffs on steel and aluminum</a> imports to 50% starting June 4. 
In corporate news, Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) reported better-than-expected third-quarter results. Meanwhile, Lyra Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares skyrocketed over 310% on Monday after its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.
On the economic front, the ISM manufacturing PMI dropped to 48.5 in May from April&#8217;s 48.7, missing market estimates of 49.5. U.S. construction spending also fell, declining 0.4% month-over-month in April to an annual rate of $2,152.4 billion, following a revised 0.8% drop in March.
The Dow Jones index ended 35 points or 0.084% higher at 42,305.48, whereas the S&amp;P 500 index rose 0.41% to 5,935.94. Nasdaq Composite advanced 0.67% to 19,242.61, and the small-cap gauge, Russell 2000, gained 0.19% to end at 2,070.16.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.67%</td>
<td>19,242.61</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.041%</td>
<td>5,935.94</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.084%</td>
<td>42,305.48</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.19%</td>
<td>2,070.16</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As the S&amp;P 500 index rebounded from its April slump, Adam Turnquist, LPL Financial's chief technical strategist, pointed to strong indicators of a genuine recovery, noting the index&#8217;s reversal of its short-term downtrend and a doubling of its uptrend during this period.
A chart from LPL Financial illustrates this shift: on April 8, the S&amp;P 500&#8217;s uptrend accounted for just 29.4%, with downtrends at 70.2%. By May 29, however, the index had swiftly recovered, with uptrends doubling to 60% and downtrends decreasing to 39%.
LPL Financial attributed this change to <a href="https://www.benzinga.com/markets/equities/25/06/45739065/sp-500-reverses-short-term-downtrend-after-april-lows-technical-evidence-shows-recovery-is-real-and-not-a-bull-trap-or-bear-market-rally">significant technical progress</a> throughout May. He explained, "The index has reversed a short-term downtrend and continues to hold above its recent price gap above the 200-day moving average (dma)."
Turnquist suggests that a close above the May high of 5,969 points could pave the way for the index to retest its previous high of 6,144 points.
He emphasized, "There is a growing list of technical evidence that suggests this recovery is real, and not a ‘bull trap' or ‘bear market rally.' For investors, this means dips above support should be used as buying opportunities."
This positive outlook follows a strong May for the broader market, which saw a 6.2% gain—its best month since November 2023 and its strongest May since 1990. Turnquist also noted that historically, when the index rallies 3% or more in May, a month often associated with the &#8220;Sell in May and Go Away&#8221; adage, year-end returns average 8.9%, with positive returns in 73% of such periods.
Meanwhile, the Senior Economist at WisdomTree and former professor at the University of Pennsylvania, Jeremy Siegel, said, &#8220;I remain bullish on equities presuming tariffs remain in the 10% for all, 30% for China, range.&#8221;
Highlighting that Trump has doubled the tariffs on steel and aluminum, Seigel added, &#8220;If he goes no further, the current upward trend can continue. The market's resilience, despite noise on tariffs, inflation, and politics, tells me that investors see the same economy I do: strong productivity, solid consumer spending, and stabilizing inflation.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s factory orders and job openings data will be out by 10:00 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee will speak at 12:45 p.m., Federal Reserve Governor Lisa Cook will speak at 1:00 p.m., and Dallas Fed President Lorie Logan will speak at 3:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) rose 1.37% in premarket on Tuesday as analysts expect it to report quarterly earnings of $1.48 per share on revenue of $10.31 billion, before the opening bell.</li>
<li>Signet Jewelers Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) was up 1.80% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of $1.03 per share on revenue of $1.52 billion.</li>
<li>Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) declined 0.99% as analysts expect it to report quarterly earnings of $2.02 per share on revenue of $7.42 billion, before the opening bell.</li>
<li>Credo Technology Group Holding Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) jumped 12.8% after reporting fourth-quarter revenue of $170.03 million, beating analyst estimates of $162.96 million.</li>
<li>MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) surged 19.05% following reports that Merck held talks to acquire the Swiss biotech company for over $3 billion.</li>
<li>Donaldson Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) fell 0.39% ahead of its earnings, which are supposed to be released before the opening bell. Analysts expect earnings of 95 cents per share on revenue of $933.45 million.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) edged 0.45% higher as analysts expect it to report quarterly earnings of 71 cents per share on revenue of $565.75 million, before the opening bell.</li>
<li>Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) was trading 0.90% higher after the successful launch of the 10th Electron mission for multi-launch customer BlackSky.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.34% to hover around $62.73 per barrel.
Gold Spot US Dollar fell 0.58% to hover around $3,361.51 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was higher by 0.21% at the 98.9110 level.
Asian markets closed mixed on Tuesday as India's S&amp;P BSE Sensex, Japan's Nikkei 225 indices declined. While South Korea's Kospi, Australia's ASX 200, China&#8217;s CSI 300, and Hong Kong's Hang Seng indices rose. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45740592/trump-sets-july-8-deadline-for-trade-deals-demands-best-offers-from-global-partners-by-wednesday-report">Trump Sets July 8 Deadline For Trade Deals, Demands Best Offers From Global Partners By Wednesday: Report</a></li>
</ul>
Photo courtesy: Shutterstock

CRDO

FERG

LYRA

MLTX

OLLI

RKLB

US Stocks Likely To Open Lower: Expert Highlights Technical Analysis Showing S&P 500's 'Recovery Is Real' And Not A 'Bull Trap' Or 'Bear Market Rally'

The snacks business of Campbell&#8217;s Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) may be facing headwinds in recent months, but one particular brand is bucking the trend.
What Happened: During the company&#8217;s <a href="https://www.benzinga.com/markets/large-cap/25/06/45720002/campbells-brews-up-strong-q3-beats-estimates-as-home-cooking-sector-simmers">third quarter earnings</a> call on Monday, Campbell&#8217;s CEO, Mick Beekhuizen, highlighted the standout performance of its Milano Cookies brand, which defied the broader slowdown in the company&#8217;s snacks segment.
The segment as a whole posted a 5% year-over-year decline in sales, but Milano premium cookie was up, and while the company does not disclose the actual sales figures for the brand, it does say that the product line &#8220;had the strongest household penetration gains&#8221; during the quarter.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45740017/tsmc-ceo-tells-trump-100-billion-us-chip-expansion-will-take-time-amid-tariff-pressures-surging-ai-demand">TSMC CEO Tells Trump $100 Billion US Chip Expansion Will &#8216;Take Time&#8217; Amid Tariff Pressures, Surging AI Demand</a>
Beekhuizen credits this to a &#8220;touch of premium indulgence&#8221; that continues to resonate with selective consumers, amid &#8220;tighter food budgets&#8221; and a broader shift towards &#8220;value.&#8221;
&#8220;Consumers are being more intentional with their discretionary snack purchases,&#8221; Beekhuizen notes, favoring products that either don&#8217;t stretch household budgets or deliver enough perceived value to justify a splurge.
The outperformance contrasts sharply with other snack brands in Campbell's portfolio, including Goldfish crackers and Snyder's of Hanover pretzels, both of which faced year-over-year sales declines. 
The company's broader snack strategy is being reworked with a focus on core brand relevance, innovation, and price-pack architecture, rather than across-the-board promotions. Executives say that while inflation and consumer caution are pressuring the segment, targeted wins like Milano reinforce the case for premium offerings.
Why It Matters: The company mentioned during the call that consumers were <a href="https://www.benzinga.com/news/retail-sales/25/06/45738876/americans-are-cooking-at-home-more-than-ever-since-covid-and-they-want-ingredients-that-stretch-their-budget">turning to its brands</a> for &#8220;value, quality, and convenience,&#8221; while also &#8220;favoring ingredients that help stretch tighter food budgets,&#8221; in light of the prevailing macro conditions. 
Milano, nonetheless, stood out, highlighting the split in consumer behavior between value and luxury in recent quarters, especially as economic conditions tightened.
During its <a href="https://www.benzinga.com/markets/large-cap/25/06/45720002/campbells-brews-up-strong-q3-beats-estimates-as-home-cooking-sector-simmers">third quarter results</a>, the company reported $2.47 billion, up 4% year-over-year, and ahead of consensus estimates at $2.43 billion. It posted a profit of $0.73 per share, ahead of analyst estimates at $0.66.
Price Action: Shares of Campbell&#8217;s Co. were up 0.62% on Monday, trading at $34.25, and are down 0.15% after hours, following its third quarter results.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="142" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM-1024x142.png" alt="" class="wp-image-936286" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM-1024x142.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM-768x107.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM-1536x214.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/03045343/Screenshot-2025-06-03-at-2.23.22-PM.png 1596w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Ranking&#8217;s the company scores poorly across most core metrics, and has an unfavorable price trend in the short, medium, and long-term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for some deeper insights into the stock. 
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45740331/trumps-man-to-man-diplomacy-wont-work-with-xi-jinping-warns-former-white-house-chief-of-staff-as-tariff-deadlock-continues">Trump&#8217;s &#8216;Man-To-Man&#8217; Diplomacy Won&#8217;t Work With Xi Jinping, Warns Former White House Chief Of Staff As Tariff Deadlock Continues</a></li>
</ul>
Photo courtesy: JHVEPhoto / Shutterstock.com

Equities

'Touch of Premium Indulgence,' Says Campbell's CEO, As 'Splurge-Worthy' Milano Cookies Defy Snack Slump

Macro Economic Events

Econ #s

Economics

Eurozone Unemployment Rate For April: 6.2% Vs. 6.2% Est.; 6.3% (Revised) Prior

Eurozone Consumer Price Index (YoY) Preliminary For May 1.9% Vs. 2.0% Est.; 2.2% Prior

Press Releases

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

Comments

Rocket Pharmaceuticals

Rocket Pharmaceuticals (RCKT) Opciones

Rocket Pharmaceuticals (NASDAQ:RCKT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL